Deucravacitinib is a selective tyrosine kinase 2 (TYK2) inhibitor, which works by targeting a specific pathway in the immune system involved in the inflammation and overproduction of skin cells seen in psoriasis. Plaque psoriasis is a chronic autoimmune condition characterized by the rapid growth of skin cells leading to red, scaly, and often itchy patches on the skin. By targeting this specific pathway, Sotyktu helps to reduce inflammation, slow down the production of skin cells, and improve the appearance and symptoms of psoriasis. This medication is typically prescribed by dermatologists and should be used under medical supervision.

The recommended dose of Sotyktu is 6 mg once daily taken orally, with or without food. Do not crush, cut, or chew the tablet.

If you miss a dose of Sotyktu, take it as soon as you remember. But if it’s almost time for your next dose, skip the missed dose and take your next dose at its usual time. If you’re not sure whether you should take a missed dose, talk with your doctor or pharmacist.

Taking too much Sotyktu (deucravacitinib) can significantly increase the risk of adverse effects and lead to serious health complications. Potential risks of overdose include increased susceptibility to infections due to excessive immune suppression, gastrointestinal issues such as nausea and vomiting, and potential impacts on liver and kidney function, leading to elevated liver enzymes or renal impairment. Other adverse effects, such as headaches and fatigue, may also become more pronounced. If an overdose is suspected, immediate medical attention is essential to provide supportive care and manage the overdose effects. Always take medications exactly as prescribed by a healthcare provider to avoid these risks.

Sotyktu (deucravacitinib) tablets should be stored at room temperature, typically between 20°C to 25°C (68°F to 77°F), away from moisture and direct sunlight. Keep the tablets in their original container with the lid tightly closed, and ensure they are out of reach of children and pets. Do not store the medication in a bathroom or other damp areas. If the medication has expired or is no longer needed, follow proper disposal methods as recommended by a pharmacist or local waste disposal company, avoiding flushing it down the toilet or pouring it into drains unless instructed.

SOTYKTU may cause serious side effects, including:

• Changes in certain laboratory test results. Changes in laboratory tests have happened in some people taking SOTYKTU. Your dermatologist may do blood tests before you start taking SOTYKTU and during treatment with SOTYKTU to check for the following:
  • Increased triglycerides. Too much fat in your blood can cause problems with your heart.
  • Increased liver enzymes. If your liver enzymes increase too much, your dermatologist may need to do additional tests on your liver and may tell you to stop taking SOTYKTU if they think that SOTYKTU is harming your liver.
• Potential risks from Janus kinase (JAK) inhibition. SOTYKTU is a tyrosine kinase 2 (TYK2) inhibitor. TYK2 is in the JAK family. It is not known whether taking SOTYKTU has the same risks as taking JAK inhibitors. Increased risk of death (all causes) has happened in people who were 50 years of age and older with at least 1 heart disease (cardiovascular) risk factor who were taking a JAK inhibitor used to treat rheumatoid arthritis (RA) compared to people taking another medicine in a class of medicines called TNF blockers. SOTYKTU is not for use in people with RA.

The most common side effects of SOTYKTU include:

Serious allergic reactions. Stop taking SOTYKTU and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:

• Common cold, sore throat, and sinus infection (upper respiratory infections)
• Cold sores (herpes simplex)
• Sores on the inner lips, gums, tongue, or roof of the mouth (canker sores)
• Inflamed hair pores (folliculitis)
• Acne

Sotyktu (deucravacitinib) may interact with other medications, potentially affecting its efficacy or increasing the risk of adverse effects. Key interactions to be aware of include:

1. Immunosuppressants: Combining Sotyktu with other immunosuppressive drugs may increase the risk of infections and other immune-related complications.

2. Biologics: Using Sotyktu alongside other biologic treatments for psoriasis or autoimmune conditions can lead to an increased risk of side effects and infections.

3. Live Vaccines: Deucravacitinib may reduce the effectiveness of live vaccines, and there's an increased risk of developing the infection the vaccine is meant to prevent.

4. Strong CYP3A4 Inducers: Medications that strongly induce the CYP3A4 enzyme (e.g., rifampin, phenytoin) can reduce the levels and effectiveness of deucravacitinib in the body.

5. Other Medications: Always inform your healthcare provider about all the medications, supplements, and herbal products you are taking to avoid potential interactions.

It is essential to consult with a healthcare professional before starting or stopping any medication while on Sotyktu to manage and mitigate potential interactions effectively.

Can I drink alcohol while taking Sotyktu?

While Sotyktu (deucravacitinib) is not known to interact directly with alcohol, drinking alcohol may trigger symptoms of psoriasis in some individuals. Since Sotyktu is used to treat plaque psoriasis, if alcohol exacerbates your symptoms, your doctor may recommend limiting or avoiding alcohol while taking Sotyktu.

How long does it take for Sotyktu to start working?

Sotyktu starts to work after your first dose. But it may take 16–24 weeks for the drug to have its maximum effect and for you to experience relief of your plaque psoriasis symptoms.

If you have other questions about what to expect from your Sotyktu treatment, talk with your doctor.

Ace provides accurate and independent information medically reviewed on prescription medications. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.